Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Frontiers Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies

AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum - ScienceDirect

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 - ScienceDirect

Dean Huang's Instagram, Twitter & Facebook on IDCrawl

A new variant alert - by Eric Topol - Ground Truths

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Frontiers Association of fat-soluble vitamins (A, D, and E) status with humoral immune response to COVID-19 inactivated vaccination

SARS-CoV-2 Omicron variant - Wikipedia

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2

Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants

Frontiers Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

WHO advisers recommend sticking with monovalent COVID XBB.1.5 vaccines